MAPK/Erk1/2 activation via C-RAF overexpression and upregulation of RTKs (PDGFRβ and IGF-1R) or N-RAS mutation have been reported to be among the mechanisms by which melanoma cells acquire resistance to B-RAF inhibitors [27]-[29]. The gene discussed is PDGFRB; the disease is melanoma.